Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Feb 1;61(2):240-245.
doi: 10.1097/SHK.0000000000002248. Epub 2023 Nov 15.

PROLONGED MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME

Affiliations
Randomized Controlled Trial

PROLONGED MECHANICAL VENTILATION IN ACUTE RESPIRATORY DISTRESS SYNDROME

Ioannis Andrianopoulos et al. Shock. .

Abstract

Purpose: Trajectory of acute respiratory distress syndrome (ARDS) spans from rapidly improving cases to cases receiving prolonged mechanical ventilation (PMV). We attempted to estimate temporal trends of prevalence and mortality of PMV and to identify risk factors associated with mortality of patients with ARDS receiving PMV. Methods: We performed a secondary analysis of individual patient data from six randomized controlled clinical trials conducted by the ARDS Network. Prolonged mechanical ventilation was defined as the need for mechanical ventilation for >21 consecutive days. Results: Of 4,216 patients with ARDS, 646 (15.3%) received PMV. Prevalence of PMV gradually declined from 18.4% in the ARDS Network: Low-Tidal-Volume Trial (published in 2000) trial to 10.9% in the SAILS (2014) trial ( R2 = 0.728, P = 0.031). Ninety-day mortality of patients receiving PMV did not change over time ( R2 = 0.271, P = 0.290) and remained as high as 36.8%. Ιn the three most recent trials, risk factors associated with mortality among the 250 patients with ARDS receiving PMV included age, malignancy, pneumonia as the cause of ARDS, coagulation dysfunction, and hepatic dysfunction during the first 21 days after trial enrollment. Conclusion: Although prevalence of PMV among patients enrolled in ARDS Network trials gradually declined, mortality did not change. Risk factors associated with mortality were mostly nonmodifiable.

PubMed Disclaimer

Conflict of interest statement

BTT received grants from the National Heart, Lung, and Blood Institute and personal fees from Bayer, Novartis, and Genentech outside the submitted work. The other authors report no conflict of interests.

References

    1. Torres LK, Hoffman KL, Oromendia C, et al. Attributable mortality of acute respiratory distress syndrome: a systematic review, meta-analysis and survival analysis using targeted minimum loss-based estimation. Thorax . 2021;76:1176–1185.
    1. Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med . 2017;377:562–572.
    1. Schenck EJ, Oromendia C, Torres LK, et al. Rapidly improving ARDS in therapeutic randomized controlled trials. Chest . 2019;155:474–482.
    1. Gavrielatou E, Vaporidi K, Tsolaki V, et al. Rapidly improving acute respiratory distress syndrome in COVID-19: a multi-centre observational study. Respir Res . 2022;23:94.
    1. Sanchez E, Price DR, Chung K-P, et al. Persistent severe acute respiratory distress syndrome for the prognostic enrichment of trials. PLoS One . 2020;15:e0227346.

Publication types

MeSH terms

LinkOut - more resources